<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517930</url>
  </required_header>
  <id_info>
    <org_study_id>19625</org_study_id>
    <nct_id>NCT03517930</nct_id>
  </id_info>
  <brief_title>A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Crossover Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D® 12-Hour Extended Release Tablet (Loratadine 5mg/Pseudoephedrine Sulfate 120 mg, Manufacturer-SAG) to a Single Oral Dose of Claritin-D® 12-Hour Extended Release Tablet (Loratadine 5 mg/Pseudoephedrine Sulfate 120 mg, Manufacturer-Heist) Under Fasted Conditions in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the bioequivalence of one extended release combination (loratadine 5
      mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer HealthCare LLC by SAG
      Manufacturing, S.L.U. Madrid, Spain (test treatment) to the extended release combination
      (loratadine 5 mg/pseudoephedrine sulfate 120 mg) tablet manufactured for Bayer SA-NV by
      Schering-Plough Labo NV Heist (reference treatment) which is currently marketed in Europe.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2018</start_date>
  <completion_date type="Anticipated">May 23, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-tlast) of loratadine and pseudoephedrine</measure>
    <time_frame>Baseline (within 60 minutes of dosing) and at 15, 30, 45, 60 minutes and 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose in each treatment period</time_frame>
    <description>Area under the curve from time 0 to the last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of loratadine and pseudoephedrine</measure>
    <time_frame>Baseline (within 60 minutes of dosing) and at 15, 30, 45, 60 minutes and 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose in each treatment period</time_frame>
    <description>Maximum observed plasma level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CL/F for loratadine, pseudoephedrine and desloratadine</measure>
    <time_frame>Baseline (within 60 minutes of dosing) and at 15, 30, 45, 60 minutes and 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose in each treatment period</time_frame>
    <description>Total body oral clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse event</measure>
    <time_frame>Up to 26 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUC(tlast-∞) for loratadine, pseudoephedrine and desloratadine</measure>
    <time_frame>Baseline (within 60 minutes of dosing) and at 15, 30, 45, 60 minutes and 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose in each treatment period</time_frame>
    <description>Percentage of AUC from last data point &gt; lower limit of quantification (LLOQ) to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for loratadine, pseudoephedrine and desloratadine</measure>
    <time_frame>Baseline (within 60 minutes of dosing) and at 15, 30, 45, 60 minutes and 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose in each treatment period</time_frame>
    <description>Time at which Cmax is observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tlast for loratadine, pseudoephedrine and desloratadine</measure>
    <time_frame>Baseline (within 60 minutes of dosing) and at 15, 30, 45, 60 minutes and 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose in each treatment period</time_frame>
    <description>Time point for last measurable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz for loratadine, pseudoephedrine and desloratadine</measure>
    <time_frame>Baseline (within 60 minutes of dosing) and at 15, 30, 45, 60 minutes and 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose in each treatment period</time_frame>
    <description>Terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 for loratadine, pseudoephedrine and desloratadine</measure>
    <time_frame>Baseline (within 60 minutes of dosing) and at 15, 30, 45, 60 minutes and 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose in each treatment period</time_frame>
    <description>Half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlast) for desloratadine</measure>
    <time_frame>Baseline (within 60 minutes of dosing) and at 15, 30, 45, 60 minutes and 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose in each treatment period</time_frame>
    <description>Area under the curve from time 0 to the last measurable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for desloratadine</measure>
    <time_frame>Baseline (within 60 minutes of dosing) and at 15, 30, 45, 60 minutes and 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose in each treatment period</time_frame>
    <description>Maximum observed plasma level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for loratadine, pseudoephedrine and desloratadine</measure>
    <time_frame>Baseline (within 60 minutes of dosing) and at 15, 30, 45, 60 minutes and 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours post dose in each treatment period</time_frame>
    <description>Area under the curve from time 0 to infinity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Clinical Pharmacology</condition>
  <arm_group>
    <arm_group_label>Test treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult subjects under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy adult subjects under fasted conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)</intervention_name>
    <description>Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)</description>
    <arm_group_label>Test treatment</arm_group_label>
    <arm_group_label>Reference treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)</intervention_name>
    <description>Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)</description>
    <arm_group_label>Test treatment</arm_group_label>
    <arm_group_label>Reference treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult men or women

          -  Age 18 to 55 years inclusive

          -  Body mass index 18.5 to 30.0 kg/m*2 inclusive

        Exclusion Criteria:

          -  Positive alcohol or drug screen at Screening or on Day -1 of each dosing period;

          -  Use of within 1 month before first study drug administration, systemic or topical
             medicines or substances which might affect the study objectives, any drug known to
             induce cytochrome P3A4/5 or P Glycoprotein (e.g., rifampin, carbamazepine, St. John's
             wort); Any drug known to inhibit cytochrome P3A4/5 or P Glycoprotein (e.g.,
             clarithromycin, chloramphenicol, ketoconazole);

          -  History of hypersensitivity symptoms with the use of loratadine, desloratadine
             (Clarinex), or pseudoephedrine;

          -  Females who are pregnant or lactating

          -  Known severe allergies (e.g., allergies to more than 3 allergens, allergies affecting
             the lower respiratory tract - allergic asthma, allergies requiring therapy with
             corticosteroids);

          -  More than moderate alcohol consumption (&gt;40 g of alcohol regularly per day);

          -  Any history or suspicion of barbiturate, amphetamine, benzodiazepine, cocaine,
             opiates, methamphetamine or cannabis abuse;

          -  Loss of blood of 50 mL to 499 mL within 30 days of the first dose of trial treatment,
             or in excess of 500 mL within 56 days of the first dose of trial treatment (e.g.,
             donation, plasmapheresis or injury)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+)1-888-84 22937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For trial location information (Phone Menu Options '3' or '4')</last_name>
    <phone>(+)1-888-84 22937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Frontage Clinical Services</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Upper respiratory allergy symptoms including congestion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

